Erratum: Long-acting antituberculous therapeutic nanoparticles target macrophage endosomes (FASEB Journal (2014) 28 (5071-5082) DOI: 10.1096/fj.14-255786);Long-acting antituberculous therapeutic nanoparticles target macrophage endosomes

FASEB Journal

Volumn 28, Issue 12, 2014, Pages 5071-5082

  Edagwa, Benson J ^a   Guo, Dongwei ^a   Puligujja, Pavan ^a   Chen, Han ^b   McMillan, JoEllyn ^a   Liu, Xinming ^a   Gendelman, Howard E ^a   Narayanasamy, Prabagaran ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

Immunoisolation; MDM; Mycobacterium smegmatis; Mycobacterium tuberculosis; Subcellular trafficking

Indexed keywords

ETHAMBUTOL; ISONIAZID; NANOCARRIER; PYRAZINAMIDE; RIFAMPICIN; NANOPARTICLE; TUBERCULOSTATIC AGENT;

ANTIMICROBIAL ACTIVITY; ARTICLE; CELL VIABILITY; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; ENDOSOME; HUMAN; HUMAN CELL; MACROPHAGE; MYCOBACTERIOSIS; MYCOBACTERIUM SMEGMATIS; PHYSICAL CHEMISTRY; CELL CULTURE; CELL FRACTIONATION; DRUG EFFECTS; METABOLISM;

MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS;

ANTITUBERCULAR AGENTS; CELLS, CULTURED; ENDOSOMES; HUMANS; MACROPHAGES; NANOPARTICLES; SUBCELLULAR FRACTIONS;

EID: 84919784607     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.14-255786ERR     Document Type: Erratum

References (61)

1. Pawlowski, A., Jansson, M., Skold, M., Rottenberg, M. E., and Kallenius, G. (2012) Tuberculosis and HIV co-infection. PLoS Pathogens 8, e1002464
2. Yager, P., Domingo, G. J., and Gerdes, J. (2008) Point-of-care diagnostics for global health. Ann. Rev. Biomed. Eng. 10, 107-144
3. Lawn, S. D., and Zumla, A. I. (2011) Tuberculosis. Lancet 378, 57-72
4. Dye, C. (2006) Global epidemiology of tuberculosis. Lancet 367, 938-940
5. Getahun, H., Gunneberg, C., Granich, R., and Nunn, P. (2010) HIV infection-associated tuberculosis: the epidemiology and the response. Clin. Infect. Dis. 50(Suppl. 3), S201-S207
6. Gupta, R., Kim, J. Y., Espinal, M. A., Caudron, J. M., Pecoul, B., Farmer, P. E., and Raviglione, M. C. (2001) Public health. Responding to market failures in tuberculosis control. Science 293, 1049-1051
7. Lienhardt, C., Glaziou, P., Uplekar, M., Loennroth, K., Getahun, H., and Raviglione, M. (2012) Global tuberculosis control: lessons learnt and future prospects. Nat. Rev. Microbiol. 10, 407-416
8. Sosnik, A., Carcaboso, A. M., Glisoni, R. J., Moretton, M. A., and Chiappetta, D. A. (2010) New old challenges in tuberculosis: Potentially effective nanotechnologies in drug delivery. Adv. Drug Delivery Rev. 62, 547-559
9. Dube, D., Agrawal, G. P., and Vyas, S. P. (2012) Tuberculosis: from molecular pathogenesis to effective drug carrier design. Drug Discovery Today 17, 760-773
10. Narayanasamy, P., Eoh, H., Brennan, P. J., and Crick, D. C. (2010) Synthesis of 4-diphosphocytidyl-2-C-methyl-D-erythritol 2-phosphate and kinetic studies of Mycobacterium tuberculosis IspF. Chem. Biol. 17, 117-122
11. Kurosu, M., Narayanasamy, P., Biswas, K., Dhiman, R., and Crick, D. C. (2007) Discovery of 1,4-dihydroxy-2-naphthoate [corrected] prenyltransferase inhibitors: new drug leads for multidrug-resistant gram-positive pathogens. J. Med. Chem. 50, 3973-3975
12. Eoh, H., Narayanasamy, P., Brown, A. C., Parish, T., Brennan, P. J., and Crick, D. C. (2009) Expression and characterization of soluble 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase from bacterial pathogens. Chem. Biol. 16, 1230-1239
13. Edagwa, B., Wang, Y., and Narayanasamy, P. (2013) Synthesis of azide derivative and discovery of glyoxalase pathway inhibitor against pathogenic bacteria. Bioorg. Med. Chem. Lett. 23, 6138-6140
14. Smith, I. (2003) Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clin. Microbiol. Rev. 16, 463-496
15. Cooper, A. M., Mayer-Barber, K. D., and Sher, A. (2011) Role of innate cytokines in mycobacterial infection. Mucosal Immunol. 4, 252-260
16. Schlesinger, L. S. (1993) Macrophage phagocytosis of virulent but not attenuated strains of Mycobacterium tuberculosis is mediated by mannose receptors in addition to complement receptors. J. Immunol. 150, 2920-2930
17. Kang, P. B., Azad, A. K., Torrelles, J. B., Kaufman, T. M., Beharka, A., Tibesar, E., DesJardin, L. E., and Schlesinger, L. S. (2005) The human macrophage mannose receptor directs Mycobacterium tuberculosis lipoarabinomannan-mediated phagosome biogenesis. J. Exp. Med. 202, 987-999
18. Small, P. L., Ramakrishnan, L., and Falkow, S. (1994) Remodeling schemes of intracellular pathogens. Science 263, 637-639
19. Philips, J. A. (2008) Mycobacterial manipulation of vacuolar sorting. Cell. Microbiol. 10, 2408-2415
20. Clemens, D. L., and Horwitz, M. A. (1995) Characterization of the Mycobacterium tuberculosis phagosome and evidence that phagosomal maturation is inhibited. J. Exp. Med. 181, 257-270
21. Armstrong, J. A., and Hart, P. D. (1971) Response of cultured macrophages to Mycobacterium tuberculosis, with observations on fusion of lysosomes with phagosomes. J. Exp. Med. 134, 713-740
22. MacMicking, J. D., Taylor, G. A., and McKinney, J. D. (2003) Immune control of tuberculosis by IFN-gamma-inducible LRG-47. Science 302, 654-659
23. Sturgill-Koszycki, S., Schlesinger, P. H., Chakraborty, P., Haddix, P. L., Collins, H. L., Fok, A. K., Allen, R. D., Gluck, S. L., Heuser, J., and Russell, D. G. (1994) Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science 263, 678-681
24. Lillebaek, T., Dirksen, A., Vynnycky, E., Baess, I., Thomsen, V. O., and Andersen, A. B. (2003) Stability of DNA patterns and evidence of Mycobacterium tuberculosis reactivation occurring decades after the initial infection. J. Infect. Dis. 188, 1032-1039
25. Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C., and Dye, C. (2003) The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch. Int. Med. 163, 1009-1021
26. Xu, S., Cooper, A., Sturgill-Koszycki, S., van Heyningen, T., Chatterjee, D., Orme, I., Allen, P., and Russell, D. G. (1994) Intracellular trafficking in Mycobacterium tuberculosis and Mycobacterium avium-infected macrophages. J. Immunol. 153, 2568-2578
27. Russell, D. G., Barry, C. E., 3rd, and Flynn, J. L. (2010) Tuberculosis: what we don't know can, and does, hurt us. Science 328, 852-856
28. Schaible, U. E., and Kaufmann, S. H. (2007) Malnutrition and infection: complex mechanisms and global impacts. PLoS Med. 4, e115
29. El-Sadr, W. M., Perlman, D. C., Denning, E., Matts, J. P., and Cohn, D. L. (2001) A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes. Clin. Infect. Dis. 32, 623-632
30. Banyal, S., Malik, P., Tuli, H. S., and Mukherjee, T. K. (2013) Advances in nanotechnology for diagnosis and treatment of tuberculosis. Curr. Opin. Pulm. Med. 19, 289-297
31. Batrakova, E. V., Gendelman, H. E., and Kabanov, A. V. (2011) Cell-mediated drug delivery. Expert Opin. Drug Deliv. 8, 415-433
32. Gendelman, H. E., Orenstein, J. M., Baca, L. M., Weiser, B., Burger, H., Kalter, D. C., and Meltzer, M. S. (1989) The macrophage in the persistence and pathogenesis of HIV infection. AIDS 3, 475-495
33. Lenaerts, A. J., Hoff, D., Aly, S., Ehlers, S., Andries, K., Cantarero, L., Orme, I. M., and Basaraba, R. J. (2007) Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910. Antimicrob. Agents Chemother. 51, 3338-3345
34. Honeybourne, D. (1994) Antibiotic penetration into lung tissues. Thorax 49, 104-106
35. Clark, S. C. (1989) Interleukin-6. Multiple activities in regulation of the hematopoietic and immune systems. Ann. N. Y. Acad. Sci. 557, 438-443
36. De Faria, T. J., Roman, M., de Souza, N. M., De Vecchi, R., de Assis, J. V., dos Santos, A. L., Bechtold, I. H., Winter, N., Soares, M. J., Silva, L. P., De Almeida, M. V., and Bafica, A. (2012) An isoniazid analogue promotes Mycobacterium tuberculosis-nanoparticle interactions and enhances bacterial killing by macrophages. Antimicrob. Agents Chemother. 56, 2259-2267
37. Bhandari, R., and Kaur, I. P. (2012) A sensitive HPLC method for determination of isoniazid in rat plasma, brain, liver and kidney. J. Chromatogr. Sep. Tech. 3, 128
38. Calleja, I., Blanco-Prieto, M. J., Ruz, N., Renedo, M. J., and Dios-Vieitez, M. C. (2004) High-performance liquid-chromatographic determination of rifampicin in plasma and tissues. J. Chromatogr. A 1031, 289-294
39. Balkundi, S., Nowacek, A. S., Veerubhotla, R. S., Chen, H., Martinez-Skinner, A., Roy, U., Mosley, R. L., Kanmogne, G., Liu, X., Kabanov, A. V., Bronich, T., McMillan, J., and Gendelman, H. E. (2011) Comparative manufacture and cell-based delivery of antiretroviral nanoformulations. Int. J. Nanomed. 6, 3393-3404
40. Xu, P., Gullotti, E., Tong, L., Highley, C. B., Errabelli, D. R., Hasan, T., Cheng, J. X., Kohane, D. S., and Yeo, Y. (2009) Intracellular drug delivery by poly(lactic-co-glycolic acid) nanoparticles, revisited. Mol. Pharm. 6, 190-201
41. Dou, H., Destache, C. J., Morehead, J. R., Mosley, R. L., Boska, M. D., Kingsley, J., Gorantla, S., Poluektova, L., Nelson, J. A., Chaubal, M., Werling, J., Kipp, J., Rabinow, B. E., and Gendelman, H. E. (2006) Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood 108, 2827-2835
42. Gendelman, H. E., Orenstein, J. M., Martin, M. A., Ferrua, C., Mitra, R., Phipps, T., Wahl, L. A., Lane, H. C., Fauci, A. S., Burke, D. S., Skillman, D., and Meltzer, M. S. (1988) Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J. Exp. Med. 167, 1428-1441
43. Kumar, B. D., Prasad, C. E., and Krishnaswamy, K. (1992) Detection of rifampicin-induced nephrotoxicity by N-acetyl-3-D-glucosaminidase activity. J. Trop. Med. Hyg. 95, 424-427
44. Olakanmi, O., Britigan, B. E., and Schlesinger, L. S. (2000) Gallium disrupts iron metabolism of mycobacteria residing within human macrophages. Infect. Immun. 68, 5619-5627
45. Kadiu, I., Nowacek, A., McMillan, J., and Gendelman, H. E. (2011) Macrophage endocytic trafficking of antiretroviral nanoparticles. Nanomedicine (Lond.) 6, 975-994
46. Nowacek, A., Kadiu, I., McMillan, J., and Gendelman, H. E. (2013) Immunoisolation of nanoparticles containing endocytic vesicles for drug quantitation. Methods Mol. Biol. 991, 41-46
47. Ehlers, S. (2009) Lazy, dynamic or minimally recrudescent? On the elusive nature and location of the mycobacterium responsible for latent tuberculosis. Infection 37, 87-95
48. Crowle, A. J., Dahl, R., Ross, E., and May, M. H. (1991) Evidence that vesicles containing living, virulent Mycobacterium tuberculosis or Mycobacterium avium in cultured human macrophages are not acidic. Infect. Immun. 59, 1823-1831
49. Hart, P. D., Young, M. R., Gordon, A. H., and Sullivan, K. H. (1987) Inhibition of phagosome-lysosome fusion in macrophages by certain mycobacteria can be explained by inhibition of lysosomal movements observed after phagocytosis. J. Exp. Med. 166, 933-946
50. Shive, M. S., and Anderson, J. M. (1997) Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev. 28, 5-24
51. Smith, S. J., Lee, A. J., Maddix, D. S., and Chow, A. W. (1999) Pill-induced esophagitis caused by oral rifampin. Ann. Pharmacother. 33, 27-31
52. Morgan, J. R., Clarke, K. W., and Brear, S. G. (1993) Phenomenon of rifampicin-induced discolouration of body fluids. Respir. Med. 87, 320-321
53. Hearn, M. J., Cynamon, M. H., Chen, M. F., Coppins, R., Davis, J., Kang, H. J.-O., Noble, A., Tu-Sekine, B., Terrot, M. S., Trombino, D., Thai, M., Webster, E. R., and Wilson, R. (2009) Preparation and antitubercular activities in vitro and in vivo of novel Schiff bases of isoniazid. Eur. J. Med. Chem. 44, 4169-4178
54. Pandey, R., and Ahmad, Z. (2011) Nanomedicine and experimental tuberculosis: facts, flaws, and future. Nanomed. Nanotech. Biol. Med. 7, 259-272
55. Nowacek, A. S., Miller, R. L., McMillan, J., Kanmogne, G., Kanmogne, M., Mosley, R. L., Ma, Z., Graham, S., Chaubal, M., Werling, J., Rabinow, B., Dou, H., and Gendelman, H. E. (2009) NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery. Nanomedicine (Lond.) 4, 903-917
56. Venugopal, J., Prabhakaran, M. P., Low, S., Choon, A. T., Zhang, Y. Z., Deepika, G., and Ramakrishna, S. (2008) Nanotechnology for nanomedicine and delivery of drugs. Curr. Pharm. Des. 14, 2184-2200
57. Yu, S. S., Lau, C. M., Thomas, S. N., Jerome, W. G., Maron, D. J., Dickerson, J. H., Hubbell, J. A., and Giorgio, T. D. (2012) Size- and charge-dependent non-specific uptake of PEGylated nanoparticles by macrophages. Int. J. Nanomed. 7, 799-813
58. Clift, M. J., Rothen-Rutishauser, B., Brown, D. M., Duffin, R., Donaldson, K., Proudfoot, L., Guy, K., and Stone, V. (2008) The impact of different nanoparticle surface chemistry and size on uptake and toxicity in a murine macrophage cell line. Toxicol. Appl. Pharmacol. 232, 418-427
59. Lei, B., Wei, C. J., and Tu, S. C. (2000) Action mechanism of antitubercular isoniazid. Activation by Mycobacterium tuberculosis KatG, isolation, and characterization of inha inhibitor. J. Biol. Chem. 275, 2520-2526
60. Vilcheze, C., and Jacobs, W. R., Jr. (2007) The mechanism of isoniazid killing: clarity through the scope of genetics. Ann. Rev. Microbiol. 61, 35-50
61. Pandey, R., Zahoor, A., Sharma, S., and Khuller, G. K. (2003) Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis (Edinb.) 83, 373-378